ClinicalTrials.Veeva

Menu
R

Retina-Vitreous Associates Medical Group | Beverly Hills, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
ranibizumab
UBX1325
NT-501
Lampalizumab
Faricimab
BI 764524
-Ranibizumab
bevacizumab
IONIS-FB-LRx

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 76 total trials
Locations recently updated

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks...

Active, not recruiting
Diabetic Macular Edema
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Drug: Ranibizumab refill exchange
Locations recently updated

Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerabi...

Active, not recruiting
Diabetic Macular Edema
Drug: Ranibizumab
Other: Sham Procedure

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling
Geographic Atrophy
Biological: OpRegen

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting
Edema
Diabetic Macular Edema
Drug: foselutoclax
Drug: Aflibercept
Locations recently updated

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with ne...

Enrolling
Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Enrolling
Diabetic Retinopathy (DR)
Genetic: RGX-314 Dose 1
Genetic: RGX-314 Dose 2

Trial sponsors

Roche logo
Jaeb Center for Health Research logo
N
AbbVie logo
Boehringer Ingelheim logo
Genentech logo
U
C
K
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems